Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3106 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Exactech completes sale of common stock

The sale resulted in gross proceeds of approximately $20.2 million and net proceeds of approximately $18.8 million after offering expenses and placement agency fees. Exactech expects to use

Stemcell licenses Geron’s intellectual property

The non-exclusive license provides Stemcell with rights under certain Geron’s patents to develop, manufacture and sell cell culture media and matrix surfaces for research use only. Geron will

Progen resumes Phase I cancer trial

Progen has commenced development of PG-11047 (formerly CGC-11047), following the acquisition of Cellgate, in early 2008. The first patient to be recruited into the trial re-initiation has been

Mylan launches generic antidepressant drug

Paroxetine hydrochloride (HCl) extended-release (ER) tablet is a generic version of GlaxoSmithKline’s (GSK) Paxil CR. As the first company to successfully file an abbreviated new drug application (ANDA)